Preclinical Trial Product Applications

Following extensive research and development, Biostage has evolved its technology to optimize the interaction of mesenchymal stem cells seeded on a biocompatible scaffold. Preclinical studies suggest that, once implanted, the scaffold seeded with the patient’s own cells signals the stem cell niche to guide the regeneration of a biological ...

By Harvard Apparatus Regenerative Technology, Inc. formely known as Biostage, Inc. based in Holliston, MASSACHUSETTS (USA).

Thermal Management: Pyroid HT pyrolytic graphite thermal spreaders and thermal vias are a powerful new material solution in the battle against thermal heat in state-of-the-art electronic circuits and devices. HT material matches the heat spreading capability of CVD diamond at 1700 W/mK but at substantially better economics. ...

By CETCO based in New York, NEW YORK (USA).

When you’re developing the next generation of small molecule therapeutics, biologics, or vaccines, getting reliable data is critical for success. So is speed. With products and services that can boost productivity, support regulatory compliance, and shorten time-to-market while ensuring high-quality assay results, Artel is helping BioPharma teams get ahead and stay ...

By Artel, Inc. by Advanced Instruments based in Westbrook, MAINE (USA).

Ventricular Tachycardia (VT) is a complex condition that has many underlying causes, varying degrees of symptoms, and potentially fatal outcomes if not treated effectively. ...

By Thermedical, Inc. based in Waltham, MASSACHUSETTS (USA).

Anesthesiologist Dr. Egbert Mik, building on his invention made together with Dr. Michiel Sinaasappel, developed the protoporphyrin IX triplet state lifetime technique (PpIX-TSLT). It is the first practical way to clinically measure oxygen availability and consumption where oxygen is needed: in the tissue cells rather than in the blood. It uses the oxygen dependent duration of the 'glow-in-the-dark' of the precursor to heme. This protoporphyrin IX is metabolized in epidermal mitochondria after local priming with ...

By Photonics Healthcare BV based in Utrecht, NETHERLANDS.

Iconeus is leveraging its expertise in preclinical research to develop innovative clinical applications using its Iconeus One CR functional ultrasound system. ...

By Iconeus based in Paris, FRANCE.

Glooko real-world patient data for retrospective studies and a global network of 7,500+ clinics for randomized clinical ...

By Glooko, Inc. based in Palo Alto, CALIFORNIA (USA).

More than 3% of the population has unruptured cerebral aneurysms, approximately 10 million people in the US. About 30,000 rupture per year, with devastating consequences. More than 30% of patients with ruptured aneurysms die, and 4 of 7 who survive have significant disabilities. Detachable microcoils are now used in more than 70% of treated aneurysms. The risk of recurrence, or recanalization, remains surprisingly high at approximately 20-30%. Various modifications are used clinically with limited evidence that ...

By Endomimetics based in Birmingham, ALASKA (USA).

Stents are the most common cardiovascular implants used in the treatment of cardiovascular diseases. However, there are concerns about in-stent renarrowing (restenosis) with bare metal stents and late stent thrombosis and inflammatory responses with drug-eluting stents. The endothelium is the lining of the blood vessels that is a thin layer of endothelial cells and underlying nanofibrillar basement membrane. It modulates vascular tone by release of factors such as nitric oxide. With stent deployment, there is ...

By Endomimetics based in Birmingham, ALASKA (USA).

Now Mobetron is the first to offer ultra-high dose rate electron therapy for preclinical and investigational studies of FLASH radiotherapy on an established clinical radiotherapy platform. ...

By IntraOp Medical, Inc. based in Sunnyvale, CALIFORNIA (USA).

Prescriptive Use To Mitigate Radiotherapy Damage To Normal Tissue and Allow More Effective Cancer Therapy. Almost 70% of all patients with cancer receive radiotherapy alone or in combination with surgery or chemotherapy. The amount of radiation that can be used to control tumor growth, however, is limited by normal tissue damage. Development of drugs to selectively reduce radiotherapy-induced normal tissue damage may improve post-therapy quality of life and allow more aggressive radiotherapy protocols to better ...

By Chrysalis BioTherapeutics, Inc. based in Galveston, TEXAS (USA).

For many years, researchers have investigated cell and gene therapies as potential replacement therapies for severe chronic diseases. Despite major advancements in the field, these approaches carry a number of limitations including immune rejection, limited eligibility, durability and variability challenges, inability to re-dose and high manufacturing costs. To address these drawbacks, we developed our novel Shielded Living Therapeutics™ (SLTx) platform, which we believe has the potential to result in ...

By Eli Lilly and Company based in Indianapolis, INDIANA (USA).